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ABSTRACT
The data available in the literature concerning
Cryptococcus gattii in vitro antifungal susceptibility
are contradictory. We have analyzed the activity of
eight antifungal agents against 23 C. gattii clinical
isolates and compared the susceptibility profiles
with those of C. neoformans. MIC analysis (mg ⁄L)
revealed that C. gattii isolates were more suscep-
tible to amphotericin B and flucytosine than were
C. neoformans isolates. Fluconazole and other azole
compounds showed high MIC values for C. gattii.
Posaconazole displayed good activity. Further
studies are required to ascertain the predictive
value of the in vitro data presented here.
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The Cryptococcus neoformans species complex com-
prises basidiomycetous yeasts that are able to
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cause life-threatening disease of the central ner-
vous system, lung and skin. These species have
been traditionally classified into three varieties,
C. neoformans var. neoformans, C. neoformans var.
grubii and C. neoformans var. gattii, which are
morphologically undistinguishable and differ in
epidemiological and clinical presentations [1].
C. neoformans var. gattii, recently raised to spe-
cies level as C. gattii [2], has until now been
considered to be restricted to tropical and subtrop-
ical climates, and may cause infection in hosts with
normal immunity. However, the outbreak of
C. gattii infection on Vancouver Island (Canada,
2001) [3] demonstrated the importance of this spe-
cies as an infectious agent in temperate climates.
In Spain, this species is uncommon, although
several autochthonous C. gattii strains were
isolated from goats with pulmonary disease
between 1990 and 1994 [4] and from a brain
abscess in a Spanish immunocompetent patient in
2003 [5].
Regarding the C. gattii antifungal susceptibility
profile, the reported data are contradictory. To
allow adequate management of emerging infec-
tions caused by this organism, we have analyzed
the antifungal susceptibility profile of C. gattii
clinical isolates. A review of the literature con-
cerning the susceptibility of this species is also
presented.
Twenty-three C. gattii strains were included in
the study. Most of them were clinical isolates
provided by colleagues: 19 isolates were from
cerebrospinal fluid and blood of Brazilian
patients, deposited at the Instituto Adolfo Lutz,
Sao Paulo, Brazil; three isolates were provided by
A. Casadevall (New York, NY, USA), including
NIH isolates 191 (serotype C, ATCC 32608), 198
and 34 [3,6]; and one isolate was from cerebro-
spinal fluid of a Spanish farmer with underlying
lupus erythematosus. The in vitro susceptibilities
of 340 C. neoformans strains identified at the
Instituto de Salud Carlos III between 1995 and
2006 were also determined and compared.
Susceptibility testing was performed according
to the recommendations proposed by the Euro-
pean Committee for Antibiotic Susceptibility
Testing of fermentative yeasts (AFST-EUCAST,
definitive document 7.1) [7]. To improve the
growth of the strains, minor modifications were
made [8].
The antifungal agents used were amphoteri-
cin B, flucytosine, fluconazole, itraconazole,
voriconazole, ravuconazole, posaconazole and
caspofungin. Statistical differences between MIC
values were assessed using Student’s t-test.
P-values <0.01 were considered to be significant.
Geometric mean (GM), MIC ranges and MICs
inhibiting 90% (MIC90) and 50% (MIC50) of the
isolates are shown in Table 1.
High susceptibility to amphotericin B was
observed among the C. gattii strains studied
(GM 0.09, range 0.03–0.25 mg ⁄L). Only one strain
showed in vitro resistance to flucytosine
(MIC ‡32 mg ⁄L). On the other hand, fluconazole
showed poor activity, with MIC values higher than
4 mg ⁄L for 21 of 23 isolates (91%). Among the new
azole compounds, posaconazole displayed what
was perhaps the highest activity, with MICs
ranging between 0.03 and 0.5 mg ⁄L (Table 1).
C. neoformans isolates showed higher MIC
values for amphotericin B and flucytosine than
C. gattii isolates (GM of 0.24 and 4.47 mg ⁄L
respectively, P <0.01). Twenty strains (5.8%)
showed MIC values for amphotericin B higher
than 1 mg ⁄L, and 6% (21 ⁄ 340) were resistant to
flucytosine (MIC ‡32 mg ⁄L). However, the
C. neoformans isolates exhibited MIC values for
itraconazole, voriconazole, ravuconazole, posaco-
nazole, and even fluconazole, that were signifi-
cantly lower than those of C. gattii (Table 1). The
Table 1. Geometric means (GMs) of MIC values (mg ⁄L), MIC ranges and MICs inhibiting 90% (MIC90) and 50% (MIC50),
respectively, of the isolates included in this study
Antifungal agent
Cryptococcus gattii (n = 23) Cryptococcus neoformans (n = 340)
GM Range MIC90 MIC50 GM Range MIC90 MIC50
Amphotericin B 0.09 0.03–0.25 0.125 0.125 0.24 0.03–4 1 0.25
Flucytosine 1.52 0.25–32 16 1 4.47 0.12 to >64 16 4
Fluconazole 15.52 4 to >64 25.6 16 7.57 0.12 to >64 16 8
Itraconazole 0.44 0.12–2 1 0.5 0.25 0.015–2 1 0.5
Voriconazole 0.47 0.03–1 1 0.5 0.12 0.015–4 0.5 0.125
Ravuconazole 0.41 0.03–2 2 0.5 0.15 0.015–4 1 0.125
Posaconazole 0.26 0.03–0.5 0.5 0.25 0.15 0.015–2 0.5 0.125
Caspofungin 17.51 8 to >16 >16 16 18.37 8 to >16 >16 16
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former showed MIC values of >4 mg ⁄L for 68%
of the isolates (232 ⁄ 340). Caspofungin was inac-
tive against both species.
In this study, C. gattii was more susceptible
than C. neoformans to amphotericin B and flucy-
tosine. Comparative studies performed to deter-
mine differences in in vitro antifungal
susceptibilities are scarce, and the results are
contradictory. Major discrepancies were identi-
fied concerning amphotericin B and flucytosine.
Eight reports were found in the literature,
including findings with clinical and environmen-
tal isolates of C. gattii [9–16]. Some studies found
very similar MICs for both species [9,13]. Others
reported C. gattii as less susceptible to some
antifungals than C. neoformans [10–12,14,16].
The method used for MIC determination influ-
ences the in vitro susceptibility pattern observed.
Although the standardized CLSI methodology for
Candida spp. has proved to be reliable, there are
still technical problems with Cryptococcus. For this
reason, MIC data obtained from different labora-
tories cannot be directly compared, because of the
variability in methods used and the absence of
standardized approaches, especially with respect
to the growth medium. Odds et al. showed that
oxygen is absolutely required for adequate growth
of Cryptococcus in RPMI medium [17] and that
agitation led to a substantial improvement in the
growth rate of the yeast. This indicates that
methods providing better growth rates facilitate
endpoint determination and MIC reproducibility.
The Etest has proven to be an excellent method
for Cryptococcus spp. susceptibility testing. In
agreement with our findings, Tay et al. showed
a collection of C. gattii strains to be highly
susceptible to amphotericin B (MIC <0.5 mg ⁄L)
using the Etest, and also found a high percentage
of C. gattii isolates with higher resistance to
fluconazole, when compared with C. neoformans
[15]. The susceptibility testing method used here
included a larger inoculum as well as agitation,
and may represent a good alternative for Crypto-
coccus susceptibility testing, as it allows faster
determination of the MIC endpoint.
However, with use of the Etest, contradictory
results have also been reported [11]. The reason
for these discrepancies could be related to differ-
ences in the origins of the yeasts. Some environ-
mental C. gattii strains produced more rapid and
intense pigmentation than did C. neoformans [18],
which correlated with higher resistance to
amphotericin B and fluconazole. Previous reports
have demonstrated that melanization reduces
susceptibility to amphotericin B [19]. In addition,
clinical antifungal resistance during therapy or
prophylaxis has been reported [20].
In summary, it is shown in this study that
amphotericin B and flucytosine have potent activ-
ity against C. gattii clinical isolates. It is also
interesting to point out the occurrence of low
MICs of posaconazole. Some modifications of the
susceptibility testing method are provided that
could allow more accurate determination of the
susceptibility profile of C. neoformans, although
further studies are needed to validate the clinical
predictive value of the in vitro data presented.
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